The U.S. Food and Drug Administration approved Arrowhead Pharmaceuticals’ RNAi therapy plozasiran (Redemplo) for familial chylomicronemia syndrome (FCS), making Arrowhead a commercial‑stage RNAi company. Arrowhead priced Redemplo substantially below a competing Ionis product, triggering immediate market attention and signaling an aggressive commercial pricing strategy that could reshape the rare lipid disorder market. The approval concludes decades of development for Arrowhead’s RNAi platform and sets up payer negotiations and uptake dynamics that will test pricing durability versus Ionis’ incumbent. Investors and industry watchers flagged the approval as validation of RNAi therapeutics beyond established hepatology targets and as a potential catalyst for further RNAi commercialization efforts.